Anaphylaxis is a rapid-onset allergic reaction that can be life threatening, and its rate of occurrence is increasing, especially in younger people.[@b1-tcrm-9-149],[@b2-tcrm-9-149] Though the financial impact of anaphylaxis can be difficult to determine, since this condition is likely underreported and underdiagnosed,[@b2-tcrm-9-149],[@b3-tcrm-9-149] the economic burden of anaphylaxis in the United States was estimated in 2010 at US\$1.2 billion in direct expenditures.[@b4-tcrm-9-149] As anaphylactic reactions often occur in community settings without ready access to a health care professional, the World Health Organization and all published national (US) guidelines list epinephrine as the only first-line option for the initial treatment of anaphylaxis.[@b1-tcrm-9-149] Epinephrine acts to prevent and relieve upper-airway obstruction and alleviate shock. Intramuscular injection into the thigh is a recommended route of administration,[@b5-tcrm-9-149] and epinephrine autoinjectors are the primary component of emergency preparedness for anaphylaxis.[@b1-tcrm-9-149] Timely and proper injection of epinephrine is critical to prevent serious consequences such as hospitalizations or death.[@b1-tcrm-9-149] Fatalities from anaphylaxis can occur in a time frame ranging from 5 to 30 minutes depending on the type of allergen exposure.[@b6-tcrm-9-149] Considering the importance of rapid absorption of epinephrine, how best should the delivery of epinephrine be evaluated when assessing the bioequivalence (BE) of a new autoinjector device?

The US Food and Drug Administration (FDA) reviewed the bioavailability of epinephrine from the Auvi-Q™ autoinjector (Sanofi, Bridgewater, NJ, USA) compared with that of the EpiPen^®^ autoinjector. This assessment was based on study INT0802, a randomized, single-dose, single-blind, two-treatment, crossover study to document the bioavailability of epinephrine delivered by Auvi-Q and EpiPen.[@b7-tcrm-9-149],[@b8-tcrm-9-149] The study design and analysis used the scaled BE approach by Haidar et al,[@b9-tcrm-9-149] which is currently recommended by the FDA for high-variability substances such as epinephrine (ie, intrasubject variability \> 30%). Seventy-one individuals were included in the pharmacokinetic (PK) data analysis; 67 individuals received dosing with Auvi-Q, while 69 subjects received at least one dose using the EpiPen.

The primary PK parameters for BE assessment were peak drug concentration (C~max~) and area under the curve (AUC); baseline correction was performed to adjust for endogenous levels of epinephrine. Secondary partial AUC parameters were also determined for each individual's concentration--time profiles by calculating the AUC from time zero to the time of the maximum plasma concentration (T~max~) after injection with the EpiPen. Partial AUC values were higher for the EpiPen than for the Auvi-Q. As shown in [Table 1](#t1-tcrm-9-149){ref-type="table"}, BE may be concluded for C~max~ and concentration--time curve from baseline to the last measurable concentration (AUC~0--t~) and AUC from baseline extrapolated to infinity (AUC~inf~). However, BE was not concluded for the partial AUC analyses based on zero to T~max~ of reference after first administration (R1ACOTMX) or based on zero to T~max~ of reference after second administration (R2ACOTMX).

Further, based on median T~max~ parameters, peak epinephrine concentrations for EpiPen occurred 10 minutes after dosing (0.170 hours, range 0.07--1.00) while peak concentrations for Auvi-Q occurred 20 minutes after dosing (0.330 hours, range 0.08--1.00). While this difference was not considered significant, a numeric T~max~ difference may be highly critical to the therapeutic efficacy of epinephrine administration.

The PK parameters C~max~, AUC~0--t~, and AUC~inf~ for Auvi-Q and EpiPen, which met the equivalence criteria using the baseline-corrected data set, were presented by Edwards et al at the American Academy of Allergy, Asthma, and Immunology annual meeting.[@b10-tcrm-9-149] This presentation did not specifically comment on partial AUC analyses, which failed to meet the BE threshold.[@b10-tcrm-9-149] However, given the clinical significance of rapid epinephrine delivery, additional PK parameters such as T~max~ and partial AUC analysis may be considered as a requirement for BE. When there is a need for rapid absorption of a life-saving medication, in the case of fast-acting, highly variable therapeutics, additional PK factors might be important to evaluate when assessing BE.
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###### 

Baseline corrected results for comparison of Auvi-Q™ (Sanofi, Bridgewater, NJ, USA) to EpiPen^®^ (Mylan Specialty LP, Basking Ridge, NJ, USA) autoinjectors

                       90% confidence interval                                                               
  ----------- -------- ------------------------- -------- --------- -------- --------- ------- ------ ------ -----
  C~max~      0.9446   0.8439                    1.0844   −0.0570   0.1931   −0.1046   43.94   Pass   Pass   Yes
  AUC~0--t~   1.1544   1.0575                    1.2774   0.1436    0.1279   −0.0373   35.76   Pass   Pass   Yes
  AUC~inf~    1.1747   1.0915                    1.3693   0.1610    0.1250   −0.0179   35.36   Pass   Pass   Yes
  R1ACOTMX    0.7635   0.6549                    0.9219   −0.2698   0.3494   −0.0686   59.11   Pass   Fail   No
  R2ACOTMX    0.7896   0.6585                    0.9532   −0.2362   0.3154   −0.0670   56.16   Pass   Fail   No

**Note:** Adapted from Center for Drug Evaluation and Research. Application Number: 201739Orig1s000. *Clinical Pharmacology and Biopharmaceutics Review(s)*. Available from: <http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/201739Orig1s000ClinPharmR.pdf>. Accessed February 1, 2013.[@b7-tcrm-9-149]

**Abbreviations:** AUC~0--t~, area under the concentration--time curve from baseline to last measurable concentration in ng · h/mL; AUC~inf~, area under the concentration--time curve from baseline extrapolated to infinity in ng · h/mL; C~max~, peak drug concentration in ng/μL; CV~WR~, coefficient of variation for reference (EpiPen^®^) in percent; PK, pharmacokinetic; R1ACOTMX, partial AUC based on zero to T~max~ after first administration in ng · h/mL; R2ACOTMX, partial AUC based on zero to T~max~ after second administration in ng · h/mL; T~max~, time at maximum plasma concentration in hours; μ~R~, mean of reference (EpiPen); μ~T~, mean of test (Auvi-Q); σ~WR~^2^, intrasubject variability for reference.
